Quick Answer
Immunovant, Inc. reported Total Assets of $776.22 million for the year ending 2025.
- Immunovant, Inc. showed an increase of +16.5% in Total Assets from 2024 to 2025.
- This data is from Immunovant, Inc.'s annual report (Form 10-K), filed with the SEC on May 29, 2025.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2018: $405.0 thousand | Q2 2019: $117.42 million | Q3 2019: $117.79 million | Q4 2019: $126.62 million | Q2 2020: $290.29 million | Q3 2020: $453.90 million | Q4 2020: $433.03 million | Q2 2021: $388.03 million | Q3 2021: $566.73 million | Q4 2021: $543.18 million | Q2 2022: $458.66 million | Q3 2022: $428.15 million | Q4 2022: $456.24 million | Q2 2023: $351.22 million | Q3 2023: $292.07 million | Q4 2023: $711.45 million | Q2 2024: $589.68 million | Q3 2024: $515.71 million | Q4 2024: $420.93 million | Q1 2025: $776.22 million | Q2 2025: $661.44 million | Q3 2025: $582.96 million | Q4 2025: $1.05 billion.
- Over the full 7 years of available data (2019 to 2025), Immunovant, Inc.'s Total Assets has grown by 5,513.4%.
- Historical annual values: Fiscal year 2025: $776.22 million | Fiscal year 2024: $666.37 million | Fiscal year 2023: $405.84 million | Fiscal year 2022: $515.56 million | Fiscal year 2021: $412.49 million | Fiscal year 2020: $109.39 million | Fiscal year 2019: $13.83 million.
- Data sourced from SEC EDGAR public filings as of August 5, 2026.
Last verified: